HRP20040641A2 - An avian embryo particulate biomass for the production of virus antigens - Google Patents
An avian embryo particulate biomass for the production of virus antigens Download PDFInfo
- Publication number
- HRP20040641A2 HRP20040641A2 HR20040641A HRP20040641A HRP20040641A2 HR P20040641 A2 HRP20040641 A2 HR P20040641A2 HR 20040641 A HR20040641 A HR 20040641A HR P20040641 A HRP20040641 A HR P20040641A HR P20040641 A2 HRP20040641 A2 HR P20040641A2
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- biomass
- particles
- infectious
- disease
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 76
- 239000000427 antigen Substances 0.000 title claims description 39
- 102000036639 antigens Human genes 0.000 title claims description 39
- 108091007433 antigens Proteins 0.000 title claims description 39
- 239000002028 Biomass Substances 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 24
- 210000001161 mammalian embryo Anatomy 0.000 title claims description 22
- 241000271566 Aves Species 0.000 title claims description 14
- 238000000034 method Methods 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 239000001301 oxygen Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 11
- 241001260012 Bursa Species 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 5
- 241000725585 Chicken anemia virus Species 0.000 claims description 5
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 241000711955 Turkey rhinotracheitis virus Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 241000606767 Avibacterium paragallinarum Species 0.000 claims description 4
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 4
- 241000711902 Pneumovirus Species 0.000 claims description 4
- 241000711798 Rabies lyssavirus Species 0.000 claims description 4
- 241000702263 Reovirus sp. Species 0.000 claims description 4
- 241000132980 Turkey adenovirus 3 Species 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000010884 Bursa disease Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 241001647378 Chlamydia psittaci Species 0.000 claims 3
- 208000000655 Distemper Diseases 0.000 claims 3
- 241000711450 Infectious bronchitis virus Species 0.000 claims 3
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34333901P | 2001-12-21 | 2001-12-21 | |
| PCT/US2002/040567 WO2003055988A1 (en) | 2001-12-21 | 2002-12-18 | An avian embryo particulate biomass for the production of virus antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040641A2 true HRP20040641A2 (en) | 2004-10-31 |
Family
ID=23345706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040641A HRP20040641A2 (en) | 2001-12-21 | 2004-07-13 | An avian embryo particulate biomass for the production of virus antigens |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20040023358A1 (zh) |
| EP (2) | EP2157173A1 (zh) |
| JP (1) | JP2005514018A (zh) |
| KR (1) | KR20040070250A (zh) |
| CN (1) | CN100408675C (zh) |
| AR (1) | AR037908A1 (zh) |
| AU (1) | AU2002360659B2 (zh) |
| BR (1) | BR0215013A (zh) |
| CA (1) | CA2471131A1 (zh) |
| CO (1) | CO5590972A2 (zh) |
| HR (1) | HRP20040641A2 (zh) |
| HU (1) | HU225995B1 (zh) |
| MX (1) | MXPA04005888A (zh) |
| NZ (1) | NZ534070A (zh) |
| PL (1) | PL371381A1 (zh) |
| RS (1) | RS55404A (zh) |
| TW (1) | TWI267553B (zh) |
| WO (1) | WO2003055988A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8237946B2 (en) * | 2004-10-08 | 2012-08-07 | Sharp Laboratories Of America, Inc. | Methods and systems for imaging device accounting server redundancy |
| US20140255447A1 (en) * | 2013-03-05 | 2014-09-11 | Biomune Company | Production of avian embryo cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH638985A5 (de) * | 1979-04-10 | 1983-10-31 | Schweiz Serum & Impfinst | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
| AT393277B (de) * | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| CA2192994A1 (en) * | 1994-06-20 | 1995-12-28 | Henry D. Stone | In ovo immunization of avian embryos with oil-emulsion vaccines |
| US5698433A (en) * | 1994-11-10 | 1997-12-16 | Immuno Ag | Method for producing influenza virus and vaccine |
| JP3490536B2 (ja) * | 1995-04-21 | 2004-01-26 | 株式会社ブリヂストン | 空気入りラジアルタイヤ |
| US5672485A (en) * | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
-
2002
- 2002-12-04 US US10/309,658 patent/US20040023358A1/en not_active Abandoned
- 2002-12-13 TW TW091136088A patent/TWI267553B/zh not_active IP Right Cessation
- 2002-12-18 MX MXPA04005888A patent/MXPA04005888A/es not_active Application Discontinuation
- 2002-12-18 CN CNB028253124A patent/CN100408675C/zh not_active Expired - Fee Related
- 2002-12-18 KR KR10-2004-7009611A patent/KR20040070250A/ko not_active Application Discontinuation
- 2002-12-18 HU HU0402548A patent/HU225995B1/hu not_active IP Right Cessation
- 2002-12-18 PL PL02371381A patent/PL371381A1/xx not_active Application Discontinuation
- 2002-12-18 NZ NZ534070A patent/NZ534070A/en not_active IP Right Cessation
- 2002-12-18 AU AU2002360659A patent/AU2002360659B2/en not_active Ceased
- 2002-12-18 EP EP09005619A patent/EP2157173A1/en not_active Withdrawn
- 2002-12-18 JP JP2003556508A patent/JP2005514018A/ja active Pending
- 2002-12-18 BR BR0215013-1A patent/BR0215013A/pt not_active IP Right Cessation
- 2002-12-18 WO PCT/US2002/040567 patent/WO2003055988A1/en active IP Right Grant
- 2002-12-18 AR ARP020104953A patent/AR037908A1/es unknown
- 2002-12-18 CA CA002471131A patent/CA2471131A1/en not_active Abandoned
- 2002-12-18 EP EP02795935A patent/EP1458851A1/en not_active Withdrawn
- 2002-12-18 RS YU55404A patent/RS55404A/sr unknown
-
2004
- 2004-06-16 CO CO04056261A patent/CO5590972A2/es not_active Application Discontinuation
- 2004-07-13 HR HR20040641A patent/HRP20040641A2/hr not_active Application Discontinuation
-
2005
- 2005-12-28 US US11/320,355 patent/US20080102507A1/en not_active Abandoned
-
2009
- 2009-05-20 US US12/469,351 patent/US20090226487A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1604961A (zh) | 2005-04-06 |
| US20090226487A1 (en) | 2009-09-10 |
| CO5590972A2 (es) | 2005-12-30 |
| BR0215013A (pt) | 2004-11-09 |
| RS55404A (en) | 2006-10-27 |
| HU225995B1 (en) | 2008-02-28 |
| NZ534070A (en) | 2006-01-27 |
| AR037908A1 (es) | 2004-12-22 |
| EP2157173A1 (en) | 2010-02-24 |
| EP1458851A1 (en) | 2004-09-22 |
| US20080102507A1 (en) | 2008-05-01 |
| HUP0402548A2 (hu) | 2005-03-29 |
| AU2002360659B2 (en) | 2009-01-08 |
| CN100408675C (zh) | 2008-08-06 |
| MXPA04005888A (es) | 2004-09-13 |
| CA2471131A1 (en) | 2003-07-10 |
| TWI267553B (en) | 2006-12-01 |
| AU2002360659A1 (en) | 2003-07-15 |
| PL371381A1 (en) | 2005-06-13 |
| TW200301305A (en) | 2003-07-01 |
| WO2003055988A1 (en) | 2003-07-10 |
| KR20040070250A (ko) | 2004-08-06 |
| JP2005514018A (ja) | 2005-05-19 |
| US20040023358A1 (en) | 2004-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2749887B2 (ja) | 連続細胞系におけるｉｂｄｖの産生 | |
| JP2006296437A (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| PT904351E (pt) | Células animais e processos para a replicação de vírus influenza | |
| AU759179B2 (en) | Novel antigenic class of avian reoviruses | |
| JPH05260962A (ja) | ニワトリ貧血因子ワクチン | |
| CA2181862C (en) | Mild newcastle disease virus vaccine | |
| AU782013B2 (en) | IBDV strain for in ovo administration | |
| HRP20040641A2 (en) | An avian embryo particulate biomass for the production of virus antigens | |
| US20120107354A1 (en) | Viral vaccine and process for preparing the same | |
| EP0009277B1 (en) | Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains | |
| WO2009013551A2 (en) | Process for preparing viral vaccine | |
| JPS6244528B2 (zh) | ||
| Prasad et al. | Isolation and characterisation of herpes virus from turkeys | |
| EP1161953A2 (en) | IBDV strain for in OVO administration | |
| Toro et al. | Absence of Neutralising antibodies to duck plague virus in the commercial duck and goose populations in West Germany (1980–1985) | |
| RU2213576C1 (ru) | Способ изготовления инактивированной эмульсионной вакцины против синдрома гидроперикардита кур | |
| Catelli et al. | Unstable attenuation of live avian pneumovirus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20091208 Year of fee payment: 8 |
|
| OBST | Application withdrawn |